Nanoparticle-mediated combinatorial targeting of multiple human dendritic cell (DC) subsets leads to enhanced T cell activation via IL-15-dependent DC crosstalk

Journal of Immunology

Volumn 193, Issue 5, 2014, Pages 2297-2305

  Sehgal, Kartik ^a   Ragheb, Ragy ^b   Fahmy, Tarek M ^a,b   Dhodapkar, Madhav V ^a   Dhodapkar, Kavita M ^a,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Yale University   (United States)

^c YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AVIDIN; CD209 ANTIGEN; GAMMA INTERFERON; INTERFERON; INTERLEUKIN 15; INTERLEUKIN 6; INTERLEUKIN 8; LAMBDA INTERFERON; NANOPARTICLE; POLYGLACTIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BLOOD DENDRITIC CELL ANTIGEN 3, HUMAN; CELL ADHESION MOLECULE; CELL SURFACE RECEPTOR; DC-SPECIFIC ICAM-3 GRABBING NONINTEGRIN; IL15 PROTEIN, HUMAN; LECTIN; MEMBRANE ANTIGEN;

ARTICLE; BIOTINYLATION; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; HUMAN; HUMAN CELL; MONOCYTE; T LYMPHOCYTE ACTIVATION; CELL COMMUNICATION; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; FEMALE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MALE; T LYMPHOCYTE;

ANTIGENS, SURFACE; CELL ADHESION MOLECULES; CELL COMMUNICATION; CELLS, CULTURED; DENDRITIC CELLS; FEMALE; HUMANS; INTERLEUKIN-15; LECTINS, C-TYPE; LYMPHOCYTE ACTIVATION; MALE; NANOPARTICLES; RECEPTORS, CELL SURFACE; T-LYMPHOCYTES;

EID: 84907020114     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400489     Document Type: Article

References (46)

1. Steinman, R. M., and J. Banchereau. 2007. Taking dendritic cells into medicine. Nature 449: 419-426.
2. Palucka, K., and J. Banchereau. 2013. Human dendritic cell subsets in vaccination. Curr. Opin. Immunol. 25: 396-402.
3. Palucka, K., and J. Banchereau. 2013. Dendritic-cell-based therapeutic cancer vaccines. Immunity 39: 38-48.
4. Bandyopadhyay, A., R. L. Fine, S. Demento, L. K. Bockenstedt, and T. M. Fahmy. 2011. The impact of nanoparticle ligand density on dendritic-cell targeted vaccines. Biomaterials 32: 3094-3105.
5. Dhodapkar, M. V., M. Sznol, B. Zhao, D. Wang, R. D. Carvajal, M. L. Keohan, E. Chuang, R. E. Sanborn, J. Lutzky, J. Powderly, et al. 2014. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci. Transl. Med. 6: 232ra51.
6. Paulis, L. E., S. Mandal, M. Kreutz, and C. G. Figdor. 2013. Dendritic cell-based nanovaccines for cancer immunotherapy. Curr. Opin. Immunol. 25: 389-395.
7. Cruz, L. J., P. J. Tacken, F. Rueda, J. C. Domingo, F. Albericio, and C. G. Figdor. 2012. Targeting nanoparticles to dendritic cells for immunotherapy. Methods Enzymol. 509: 143-163.
8. Metcalfe, S. M., and T. M. Fahmy. 2012. Targeted nanotherapy for induction of therapeutic immune responses. Trends Mol. Med. 18: 72-80.
9. Ali, O. A., D. Emerich, G. Dranoff, and D. J. Mooney. 2009. In situ regulation of DC subsets and T cells mediates tumor regression in mice. Sci. Transl. Med. 1: 8ra19.
10. Kasturi, S. P., I. Skountzou, R. A. Albrecht, D. Koutsonanos, T. Hua, H. I. Nakaya, R. Ravindran, S. Stewart, M. Alam, M. Kwissa, et al. 2011. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470: 543-547.
11. Demento, S. L., S. C. Eisenbarth, H. G. Foellmer, C. Platt, M. J. Caplan, W. Mark Saltzman, I. Mellman, M. Ledizet, E. Fikrig, R. A. Flavell, and T. M. Fahmy. 2009. Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. Vaccine 27: 3013-3021.
12. Goldinger, S. M., R. Dummer, P. Baumgaertner, D. Mihic-Probst, K. Schwarz, A. Hammann-Haenni, J. Willers, C. Geldhof, J. O. Prior, T. M. Kündig, et al. 2012. Nano-particle vaccination combined with TLR-7 and-9 ligands triggers memory and effector CD8+ T-cell responses in melanoma patients. Eur. J. Immunol. 42: 3049-3061.
13. Schreibelt, G., L. J. Klinkenberg, L. J. Cruz, P. J. Tacken, J. Tel, M. Kreutz, G. J. Adema, G. D. Brown, C. G. Figdor, and I. J. de Vries. 2012. The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells. Blood 119: 2284-2292.
14. Tacken, P. J., W. Ginter, L. Berod, L. J. Cruz, B. Joosten, T. Sparwasser, C. G. Figdor, and A. Cambi. 2011. Targeting DC-SIGN via its neck region leads to prolonged antigen residence in early endosomes, delayed lysosomal degradation, and cross-presentation. Blood 118: 4111-4119.
15. Tacken, P. J., I. S. Zeelenberg, L. J. Cruz, M. A. van Hout-Kuijer, G. van de Glind, R. G. Fokkink, A. J. Lambeck, and C. G. Figdor. 2011. Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood 118: 6836-6844.
16. Cruz, L. J., P. J. Tacken, R. Fokkink, B. Joosten, M. C. Stuart, F. Albericio, R. Torensma, and C. G. Figdor. 2010. Targeted PLGA nano-but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. J. Control. Release 144: 118-126.
17. Tel, J., S. P. Sittig, R. A. Blom, L. J. Cruz, G. Schreibelt, C. G. Figdor, and I. J. de Vries. 2013. Targeting uptake receptors on human plasmacytoid dendritic cells triggers antigen cross-presentation and robust type I IFN secretion. J. Immunol. 191: 5005-5012.
18. Cruz, L. J., P. J. Tacken, J. M. Pots, R. Torensma, S. I. Buschow, and C. G. Figdor. 2012. Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN. Biomaterials 33: 4229-4239.
19. Demento, S. L., A. L. Siefert, A. Bandyopadhyay, F. A. Sharp, and T. M. Fahmy. 2011. Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines. Trends Biotechnol. 29: 294-306.
20. Dudziak, D., A. O. Kamphorst, G. F. Heidkamp, V. R. Buchholz, C. Trumpfheller, S. Yamazaki, C. Cheong, K. Liu, H. W. Lee, C. G. Park, et al. 2007. Differential antigen processing by dendritic cell subsets in vivo. Science 315: 107-111.
21. Pulendran, B., H. Tang, and T. L. Denning. 2008. Division of labor, plasticity, and crosstalk between dendritic cell subsets. Curr. Opin. Immunol. 20: 61-67.
22. Luci, C., and F. Anjuère. 2011. IFN-λs and BDCA3+/CD8α+ dendritic cells: towards the design of novel vaccine adjuvants? Expert Rev. Vaccines 10: 159-161.
23. Segura, E., M. Durand, and S. Amigorena. 2013. Similar antigen crosspresentation capacity and phagocytic functions in all freshly isolated human lymphoid organ-resident dendritic cells. J. Exp. Med. 210: 1035-1047.
24. Cohn, L., B. Chatterjee, F. Esselborn, A. Smed-Sörensen, N. Nakamura, C. Chalouni, B. C. Lee, R. Vandlen, T. Keler, P. Lauer, et al. 2013. Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+ dendritic cells at cross presentation. J. Exp. Med. 210: 1049-1063.
25. Kreutz, M., P. J. Tacken, and C. G. Figdor. 2013. Targeting dendritic cells-why bother? Blood 121: 2836-2844.
26. Fahmy, T. M., S. L. Demento, M. J. Caplan, I. Mellman, and W. M. Saltzman. 2008. Design opportunities for actively targeted nanoparticle vaccines. Nanomedicine (Lond) 3: 343-355.
27. Park, J., T. Mattessich, S. M. Jay, A. Agawu, W. M. Saltzman, and T. M. Fahmy. 2011. Enhancement of surface ligand display on PLGA nanoparticles with amphiphilic ligand conjugates. J. Control. Release: 156: 109-115.
28. Fahmy, T. M., R. M. Samstein, C. C. Harness, and W. Mark Saltzman. 2005. Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting. Biomaterials 26: 5727-5736.
29. Dhodapkar, K. M., J. L. Kaufman, M. Ehlers, D. K. Banerjee, E. Bonvini, S. Koenig, R. M. Steinman, J. V. Ravetch, and M. V. Dhodapkar. 2005. Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc. Natl. Acad. Sci. USA 102: 2910-2915.
30. Bass, A. J., H. Watanabe, C. H. Mermel, S. Yu, S. Perner, R. G. Verhaak, S. Y. Kim, L. Wardwell, P. Tamayo, I. Gat-Viks, et al. 2009. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat. Genet. 41: 1238-1242.
31. Dhodapkar, K. M., S. N. Gettinger, R. Das, H. Zebroski, and M. V. Dhodapkar. 2013. SOX2-specific adaptive immunity and response to immunotherapy in nonsmall cell lung cancer. OncoImmunology 2: e25205.
32. Spisek, R., A. Kukreja, L. C. Chen, P. Matthews, A. Mazumder, D. Vesole, S. Jagannath, H. A. Zebroski, A. J. Simpson, G. Ritter, et al. 2007. Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J. Exp. Med. 204: 831-840.
33. Pulendran, B., J. Z. Oh, H. I. Nakaya, R. Ravindran, and D. A. Kazmin. 2013. Immunity to viruses: learning from successful human vaccines. Immunol. Rev. 255: 243-255.
34. Querec, T., S. Bennouna, S. Alkan, Y. Laouar, K. Gorden, R. Flavell, S. Akira, R. Ahmed, and B. Pulendran. 2006. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med. 203: 413-424.
35. Kastenmüller, K., U. Wille-Reece, R. W. Lindsay, L. R. Trager, P. A. Darrah, B. J. Flynn, M. R. Becker, M. C. Udey, B. E. Clausen, B. Z. Igyarto, et al. 2011. Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets. J. Clin. Invest. 121: 1782-1796.
36. Lauterbach, H., B. Bathke, S. Gilles, C. Traidl-Hoffmann, C. A. Luber, G. Fejer, M. A. Freudenberg, G. M. Davey, D. Vremec, A. Kallies, et al. 2010. Mouse CD8alpha+ DCs and human BDCA3+ DCs are major producers of IFN-lambda in response to poly IC. J. Exp. Med. 207: 2703-2717.
37. Poulin, L. F., M. Salio, E. Griessinger, F. Anjos-Afonso, L. Craciun, J. L. Chen, A. M. Keller, O. Joffre, S. Zelenay, E. Nye, et al. 2010. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J. Exp. Med. 207: 1261-1271.
38. Dubsky, P., H. Saito, M. Leogier, C. Dantin, J. E. Connolly, J. Banchereau, and A. K. Palucka. 2007. IL-15-induced human DC efficiently prime melanomaspecific naive CD8+ T cells to differentiate into CTL. Eur. J. Immunol. 37: 1678-1690.
39. Sosinowski, T., J. T. White, E. W. Cross, C. Haluszczak, P. Marrack, L. Gapin, and R. M. Kedl. 2013. CD8a+ dendritic cell trans presentation of IL-15 to naive CD8+ T cells produces antigen-inexperienced T cells in the periphery with memory phenotype and function. J. Immunol. 190: 1936-1947.
40. Anguille, S., E. Lion, J. Tel, I. J. de Vries, K. Couderé, P. D. Fromm, V. F. Van Tendeloo, E. L. Smits, and Z. N. Berneman. 2012. Interleukin-15-induced CD56(+) myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential. PLoS ONE 7: e51851.
41. Colpitts, S. L., T. A. Stoklasek, C. R. Plumlee, J. J. Obar, C. Guo, and L. Lefrançois. 2012. Cutting edge: the role of IFN-α receptor and MyD88 signaling in induction of IL-15 expression in vivo. J. Immunol. 188: 2483-2487.
42. Stonier, S. W., and K. S. Schluns. 2010. Trans-presentation: a novel mechanism regulating IL-15 delivery and responses. Immunol. Lett. 127: 85-92.
43. Perera, P. Y., J. H. Lichy, T. A. Waldmann, and L. P. Perera. 2012. The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use. Microbes Infect. 14: 247-261.
44. Akkina, R. 2013. Human immune responses and potential for vaccine assessment in humanized mice. Curr. Opin. Immunol. 25: 403-409.
45. Dhodapkar, M. V., and K. M. Dhodapkar. 2011. Vaccines targeting cancer stem cells: are they within reach? Cancer J. 17: 397-402.
46. Look, M., E. Stern, Q. A. Wang, L. D. DiPlacido, M. Kashgarian, J. Craft, and T. M. Fahmy. 2013. Nanogel-based delivery of mycophenolic acid ameliorates systemic lupus erythematosus in mice. J. Clin. Invest. 123: 1741-1749.